65 related articles for article (PubMed ID: 19717753)
1. Hepatocellular adenoma: cost-effectiveness of different treatment strategies.
van der Sluis FJ; Bosch JL; Terkivatan T; de Man RA; Ijzermans JN; Hunink MG
Radiology; 2009 Sep; 252(3):737-46. PubMed ID: 19717753
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome.
Hogenhuis W; Stevens SK; Wang P; Wong JB; Manolis AS; Estes NA; Pauker SG
Circulation; 1993 Nov; 88(5 Pt 2):II437-46. PubMed ID: 8222191
[TBL] [Abstract][Full Text] [Related]
4. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of navigated radiofrequency ablation for hepatocellular carcinoma in China.
Lai Y; Li K; Li J; Liu SX
Int J Technol Assess Health Care; 2014 Oct; 30(4):400-8. PubMed ID: 25682956
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.
Thein HH; Isaranuwatchai W; Qiao Y; Wong K; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
Cancer Med; 2017 Sep; 6(9):2017-2033. PubMed ID: 28791798
[TBL] [Abstract][Full Text] [Related]
9. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis.
Molinari M; Helton S
Am J Surg; 2009 Sep; 198(3):396-406. PubMed ID: 19520354
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: a cost-utility analysis.
Bhan SN; Pautler SE; Shayegan B; Voss MD; Goeree RA; You JJ
Ann Surg Oncol; 2013 Oct; 20(11):3675-84. PubMed ID: 23720071
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.
Akamatsu M; Yoshida H; Obi S; Sato S; Koike Y; Fujishima T; Tateishi R; Imamura M; Hamamura K; Teratani T; Shiina S; Ishikawa T; Omata M
Liver Int; 2004 Dec; 24(6):625-9. PubMed ID: 15566514
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
17. Abdominal aortic aneurysms: cost-effectiveness of elective endovascular and open surgical repair.
Bosch JL; Kaufman JA; Beinfeld MT; Adriaensen ME; Brewster DC; Gazelle GS
Radiology; 2002 Nov; 225(2):337-44. PubMed ID: 12409564
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids.
Beinfeld MT; Bosch JL; Isaacson KB; Gazelle GS
Radiology; 2004 Jan; 230(1):207-13. PubMed ID: 14695395
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy.
Pham AN; Datta SK; Weber TJ; Walter LC; Colón-Emeric CS
J Am Geriatr Soc; 2011 Sep; 59(9):1642-9. PubMed ID: 21883116
[TBL] [Abstract][Full Text] [Related]
20. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
Stylopoulos N; Gazelle GS; Rattner DW
Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
